Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Supha PharmachemBOM:539561 54 Days Payable is 360.04 as of Sep. 2025, which is 362% above its 10-year median of 77.85. GuruFocus rates BOM:539561 with a GF Score™ of 54/100 and a GF Value™ of ₹1.52 (Possible Value Trap). The stock has 12 warning signs investors should review. Among 925 Drug Manufacturers companies, Supha Pharmachem ranks better than 93.73% on this metric.
The historical rank and industry rank for Supha Pharmachem's Days Payable or its related term are showing as below:
BOM:539561'
s Days Payable Range Over the Past 10 Years
Min: 1.35 Med: 77.85 Max: 2852.83
Current: 419.93
During the past 11 years, Supha Pharmachem's highest Days Payable was 2852.83. The lowest was 1.35. And the median was 77.85.
BOM:539561's Days Payable is ranked better than 93.73% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:539561: 419.93
Supha Pharmachem's Days Payable
declined
from Sep. 2024 (4,177.21) to Sep. 2025 (360.04).
It may suggest that Supha Pharmachemaccelerated paying its suppliers.
Supha Pharmachem Days Payable Related Terms
Supha Pharmachem Days Payable Historical Data
* Premium members only.
The historical data trend for Supha Pharmachem's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Supha Pharmachem's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supha Pharmachem Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supha Pharmachem's Days Payable distribution charts can be found below:
* The bar in red indicates where Supha Pharmachem's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Supha Pharmachem's Days Payable for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supha Pharmachem (BOM:539561) has a Days Payable of 360.04 as of Sep. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Supha Pharmachem and its competitors. This is 362% above median its historical median of 77.85. Over the past decade, Supha Pharmachem's Days Payable has ranged from 1.35 to 2,852.83. According to the industry distribution chart, Supha Pharmachem ranks #58 out of 925 companies in the Drug Manufacturers industry, placing it in the top 6.3%.
Is Supha Pharmachem's Days Payable too high?
Supha Pharmachem's current Days Payable of 360.04 is 362% above median its 10-year median of 77.85. Over the past 10 years, this metric has ranged from a low of 1.35 to a high of 2,852.83. The Drug Manufacturers industry median Days Payable is 90.38. Supha Pharmachem's value of 360.04 is 298.4% above this industry median. Based on the distribution chart, Supha Pharmachem ranks #58 out of 925 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Supha Pharmachem has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Supha Pharmachem's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Supha Pharmachem ranks #58 out of 925 companies for Days Payable. This places Supha Pharmachem in the top 6% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Supha Pharmachem's value of 360.04 is 298.4% above this benchmark. Historically, Supha Pharmachem's own Days Payable has ranged from 1.35 to 2,852.83 over the past decade. While the company's 10-year median is 77.85 vs. the industry median of 90.38, Supha Pharmachem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supha Pharmachem's current Days Payable of 360.04 is 298.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Supha Pharmachem and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supha Pharmachem's current Days Payable is 360.04, which is 362% above median its own 10-year median of 77.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supha Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Supha Pharmachem (BOM:539561) is currently considered Possible Value Trap. The stock's GF Value™ is ₹1.52, compared to a current price of ₹0.31 — trading 79.6% below its estimated fair value. The current Days Payable is 360.04, which is 362% above median its 10-year median of 77.85 and 298.4% above the Drug Manufacturers industry median of 90.38. Supha Pharmachem's overall GF Score™ is 54/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Supha Pharmachem (BOM:539561), the current Days Payable is 360.04 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supha Pharmachem (BOM:539561) Overvalued in 2026?
Based on GuruFocus' analysis, Supha Pharmachem stock appears to be undervalued.
The current stock price of ₹0.31 is trading 79.6% below its estimated GF Value™ of ₹1.52.
GuruFocus considers Supha Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:539561:
Days Payable: 360.04 (362% above median its 10-year median of 77.85)
GF Value™: ₹1.52 vs. price of ₹0.31 (79.6% below fair value)
Industry Position: 298.4% above the Drug Manufacturers median (#58 of 925)
No single metric tells the full story. See the BOM:539561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supha Pharmachem Ltd, formerly known as Remedium Lifecare Ltd, is engaged in the business of trading in API Intermediates (KSMs & CRMs) and various other raw materials used in API trading viz. Iso propyl Alcohol (IPA), Cyclohexane, DI Iso Propyl Amine (DIPA), Ethyl Acetate, Hydrazine Hydrate, Iso propyl Alcohol (IPA), Methylene Di Chloride, Potassium Carbonate Powder, Sodium Bi-Carbonate, Potassium Hydroxide Flakes, Sodium Chloride (Common Salt), Sodium Carbonate (SODA ASH), Amino isophthalic Acid, Tellurium(IV) Oxide, Grignard Reagent, Iodine, Selenium Metal Powder, Trimethyl Sulfoxonium Iodide (TMSI).
54GF Score
Get the complete analysis for BOM:539561
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539561 has been successfully added to your 
